Roche is hoping to challenge Biogen with a new treatment for the rare muscle wasting disease spinal muscular atrophy – and the plans just got a boost after European regulators gave it speci
The FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor to the cancer blockbuster in the US.
AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication
Pharma giant UCB is to invest around £1 billion in the UK as part of a second life sciences sector deal with the UK government, with industry names such as Roche and IQVIA also committing t
Roche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in inflammatory diseases including the fatty liver disease NASH.